

SCICLONE PHARMACEUTICALS INC

Reported by
BLOBEL FRIEDHELM

FORM 4

(Statement of Changes in Beneficial Ownership)

Filed 04/24/17 for the Period Ending 04/20/17

Address	950 TOWER LANE SUITE 900 FOSTER CITY, CA 94404-2125
Telephone	650-358-3456
CIK	0000880771
Symbol	SCLN
SIC Code	2834 - Pharmaceutical Preparations
Industry	Pharmaceuticals
Sector	Healthcare
Fiscal Year	12/31

FORM 4

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549**

OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5

[] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or
Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person * Blobel Friedhelm (Last) (First) (Middle) 950 TOWER LANE, SUITE 900 (Street) FOSTER CITY, CA 94404 (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol SCICLONE PHARMACEUTICALS INC SCLN 	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) <input checked="" type="checkbox"/> Director _____ 10% Owner <input checked="" type="checkbox"/> Officer (give title below) _____ Other (specify below) President & CEO
3. Date of Earliest Transaction (MM/DD/YYYY) <p align="center">4/20/2017</p>		6. Individual or Joint/Group Filing (Check Applicable Line) <input type="checkbox"/> Form filed by One Reporting Person <input type="checkbox"/> Form filed by More than One Reporting Person
4. If Amendment, Date Original Filed (MM/DD/YYYY)		

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Trans. Date	2A. Deemed Execution Date, if any	3. Trans. Code (Instr. 8)		4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock	4/20/2017		M	(1)	11678	A	\$3.55	104204	D	
Common Stock	4/20/2017		S	(1)	11678	D	\$9.6002	92526	D	
Common Stock	4/21/2017		M	(1)	16162	A	\$3.55	108688	D	
Common Stock	4/21/2017		S	(1)	16162	D	\$9.4747	92526	D	
Common Stock	4/24/2017		M	(1)	12160	A	\$3.55	104686	D	
Common Stock	4/24/2017		S	(1)	12160	D	\$9.6405	92526	D	

Table II - Derivative Securities Beneficially Owned (e.g. , puts, calls, warrants, options, convertible securities)

1. Title of Derivate Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Trans. Date	3A. Deemed Execution Date, if any	4. Trans. Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Non-Qualified Stock Options (right to buy) (2)	\$3.55	4/20/2017		M		11678		(3)	3/5/2020	Common Stock	11678	\$0	238722	D	
Non-Qualified Stock Options (right to buy) (2)	\$3.55	4/21/2017		M		16162		(3)	3/5/2020	Common Stock	16162	\$0	222560	D	
Non-Qualified Stock Options (right to buy) (2)	\$3.55	4/24/2017		M		12160		(3)	3/5/2020	Common Stock	12160	\$0	210400	D	

Explanation of Responses:

- (1) The reported sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 18, 2016.
- (2) Granted under the Issuer's 2005 Equity Incentive Plan.
- (3) 25% of each shares vest one year from the date of grant, of March 5, 2010, and 2.0833% vests each month thereafter, provided that Reporting Person continues to be employed by the Issuer.

Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
Blobel Friedhelm 950 TOWER LANE, SUITE 900 FOSTER CITY, CA 94404	X		President & CEO	

Signatures

/s/ Friedhelm Blobel, Ph.D.

4/24/2017

—**Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.